Donidalorsen
Brand names: Dawnzera · Active ingredient: Donidalorsen Sodium
In short: DAWNZERA™ is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
What is Donidalorsen used for?
DAWNZERA™ is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Donidalorsen dosage
The recommended dosage of DAWNZERA is 80 mg administered subcutaneously every 4 weeks.
A dosage of 80 mg administered subcutaneously every 8 weeks may be considered.
Missed Dose(s)
If a dose of DAWNZERA is missed, administer DAWNZERA as soon as possible. Resume treatment at the recommended dosing frequency from the date of the most recently administered dose.
For subcutaneous use.
DAWNZERA is intended for self-administration or administration by a caregiver. Prior to treatment initiation, train patients and/or caregivers on proper preparation and subcutaneous administration technique of DAWNZERA autoinjector
.
Remove the single‑dose autoinjector from the refrigerator 30 minutes prior to the injection and allow to warm to room temperature. Do not use other warming methods.
Inspect DAWNZERA visually for particulate matter and discoloration prior to administration. The solution should appear clear and colorless to yellow. Do not use if cloudiness, particulate matter, or discoloration is observed prior to administration.
Administer DAWNZERA subcutaneously into the abdomen or upper thigh region. The back of the upper arm can also be used as an injection site if a caregiver or healthcare provider administers the injection.
How to take Donidalorsen — instructions & advice from the label
Advise the patient to read the FDA‑approved patient labeling (Patient Information and Instructions for Use).
Administration Instructions
Instruct patients that DAWNZERA is for subcutaneous use and intended for self-administration or administration by a caregiver.
Instruct patients and/or caregivers on proper preparation and subcutaneous administration technique of DAWNZERA autoinjector
.
Instruct patients to administer DAWNZERA subcutaneously into the abdomen or upper thigh region for self-administration. The back of the upper arm can be used as an injection site if a caregiver or healthcare provider administers DAWNZERA.
Missed Dose(s)
Instruct patients to use DAWNZERA as prescribed. If a dose is missed, instruct patients to administer DAWNZERA as soon as they remember. Instruct patients to resume treatment at the recommended dosing frequency (every 4 weeks or every 8 weeks) from the date of the most recently administered dose
.
Risk of Hypersensitivity Reactions, Including Anaphylaxis
Advise patients hypersensitivity reactions, including anaphylaxis, have been reported following administration of DAWNZERA. …
Warnings & precautions
Do not take this medicine if: DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA
.
Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA
. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.
Donidalorsen side effects
The following clinically significant adverse reactions are discussed elsewhere in the labeling:
Risk of Hypersensitivity Reactions, Including Anaphylaxis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of DAWNZERA reflects the exposure in a total of 171 adult and pediatric patients 12 years and older with hereditary angioedema (HAE) from a placebo-controlled trial (OASIS-HAE)
, and 2 other clinical studies. The average duration of DAWNZERA treatment exposure across the 3 clinical studies was 14 months.
The safety data below is based on the 24-week multicenter, randomized, double-blind, placebo-controlled trial (OASIS-HAE), in which patients received at least one subcutaneous dose of DAWNZERA 80 mg once every 4 weeks (n=45), DAWNZERA 80 mg once every 8 weeks (n=23), or matching placebo (n=22). Demographics of the patients in OASIS-HAE are summarized in Clinical Studies
.
Table 1 provides the most common adverse reactions with DAWNZERA with incidence ≥5% and more common than placebo.
N = number of patients; n = number of patients experiencing the event; q4wks = every 4 weeks; q8wks = every 8 weeks. …
About this medicine
Donidalorsen is a prekallikrein-directed antisense oligonucleotide (ASO) covalently linked to a ligand containing three
N‑acetyl galactosamine (GalNAc) residues to facilitate delivery of the ASO to hepatocytes.
DAWNZERA contains donidalorsen sodium as the active ingredient. Donidalorsen sodium is a white to yellow solid and it is freely soluble in water and in sodium phosphate buffer. The molecular formula of donidalorsen sodium is C
296H
415N
83O
151P
20S
15Na
20and the molecular weight is 9112.27 daltons. The chemical name of donidalorsen is DNA, d([2′-
O-(2-methoxyethyl)]m
5rU-s
p-[2′-
O-(2-methoxyethyl)]rG-s
p-[2′-
O-(2-methoxyethyl)]m
5rC-[2′-
O-(2-methoxyethyl)]rA-[2′-
O-(2-methoxyethyl)]rA-s
p-G-s
p-T-s
p-m
5C-s
p-T-s
p-m
5C-s
p-T-s
p-T-s
p-G-s
p-G-s
p-m
5C-s
p-[2′-
O-(2-methoxyethyl)]rA-[2′-
O-(2-methoxyethyl)]rA-[2′-
O-(2methoxyethyl)]rA-s
p-[2′-
O-(2-methoxyethyl)]m
5rC-s
p-[2′-
O-(2-methoxyethyl)]rA), …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3ff501e0-f75f-07da-e063-6294a90a0cb7. Read the full official label on DailyMed.